ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ACUR Acura Pharmaceuticals Inc (CE)

0.0041
0.0011 (36.67%)
May 03 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 260
Bid Price
Ask Price
News -
Day High 0.0041

Low
0.000001

52 Week Range

High
0.05

Day Low 0.0041
Company Name Stock Ticker Symbol Market Type
Acura Pharmaceuticals Inc (CE) ACUR OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0011 36.67% 0.0041 15:39:25
Open Price Low Price High Price Close Price Prev Close
0.0041 0.0041 0.0041 0.0041 0.003
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2 260 $ 0.0041 $ 1 - 0.000001 - 0.05
Last Trade Time Type Quantity Stock Price Currency
15:39:25 200 $ 0.0041 USD

Acura Pharmaceuticals Inc (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 270.61k 66.00M 7.49M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Acura Pharmaceuticals (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ACUR Message Board. Create One! See More Posts on ACUR Message Board See More Message Board Posts

Historical ACUR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.010.010.0030.0032174403-0.0059-59.00%
1 Month0.00260.050.00260.00547916,7050.001557.69%
3 Months0.0010.050.0010.00626533,4620.0031310.00%
6 Months0.0000010.050.0000010.00290533,9170.0041409,900.00%
1 Year0.050.050.0000010.0074043,574-0.0459-91.80%
3 Years0.360.75380.0000010.35000578,934-0.3559-98.86%
5 Years0.240.75380.0000010.31452459,824-0.2359-98.29%

Acura Pharmaceuticals (CE) Description

We are an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx Technology, a devleopment stage technology, is being developed to minimize the risk of overdose. Our Aversion Technology is intended to address methods of abuse associated with opioid analgesics and our Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Nexafed brand products utilize our Impede Technology. On June 28, 2019, we entered into License, Development and Commercialization Agreement, which was amended in October 2020 and June 2021, ("AD Pharma Agreement") with Abuse Deterrent Pharma, LLC, a Kentucky limited liability company ("AD Pharma") to develop LTX-03. The AD Pharma Agreement grants exclusive commercialization rights in the United States to LTX-03 as well as to LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam). The development of LTX-03 is ongoing.

Your Recent History

Delayed Upgrade Clock